NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAS-24-058 from the NIH Guide for Grants and Contracts. The purpose of this NIDCD initiative is to encourage research in the development, characterization, and reproducibility/reliability of human auditory and vestibular organoids.Applications investigating animal organoids are allowable but only if accompanying comparative or other integrated companion studies with human organoids. Singular animal organoid studies alone are not responsive to this funding opportunity. This funding opportunity encourages innovative, reproducible, and novel methodologies and technologies that will drive the reproducibility and holistic longevity of hearing/balance sensory organoids as model systems. The development of novel tools to deliver genes, proteins, molecules, and synthetics that might lead to the successful expansion and longer-term survivability of organoid populations in a stable, reliable, and reproducible manner is highly encouraged. Subsequent characterization of the organoid platforms must be shown to mimic and recapitulate the native correlative biological function. Applications that provide approaches that remove current barriers and lessen challenges to improve current reproducibility and stability are highly encouraged. Applications that have breakthrough approaches and technologies using human auditory/vestibular organoids are highly encouraged.
Funding Opportunity PAS-24-057 from the NIH Guide for Grants and Contracts. The purpose of this NIDCD initiative is to encourage research in the development, characterization, and reproducibility/reliability of human auditory and vestibular organoids. Proposals investigating animal organoids are allowable but only if accompanying comparative or other integrated companion studies with human organoids. Singular animal organoid studies alone are not responsive to this funding opportunity. This funding opportunity encourages innovative, reproducible, and novel methodologies and technologies that will drive the reproducibility and holistic longevity of hearing/balance sensory organoids as model systems. The development of novel tools to deliver genes, proteins, molecules, and synthetics that might lead to the successful expansion and longer-term survivability of organoid populations in a stable, reliable, and reproducible manner is highly encouraged. Subsequent characterization of the organoid platforms must be shown to mimic and recapitulate the native correlative biological function. Applications that provide approaches that remove current barriers and lessen challenges to improve current reproducibility and stability are highly encouraged. Applications that have breakthrough approaches and technologies using human auditory/vestibular organoids are highly encouraged.
Funding Opportunity RFA-AI-23-060 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support the late-stage engineering and preclinical development of innovative biological products that safely and specifically kill HIV-infected cells. Products of interest include but are not limited to broadly neutralizing antibodies (bNAbs), their derivatives, and other soluble, antibody-like molecules.
Funding Opportunity RFA-AI-23-061 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to accelerate the development of safe and effective long-acting drug delivery systems for improved, simplified treatment of HIV-1 in children. This NOFO invites applicants engaged in the development of existing long-acting platforms at early stages of development stages to perform specific preclinical activities that enable product optimization and accelerated translation to HIV-infected children. Collaborative research partnerships with industry are required.
Notice NOT-MH-24-290 from the NIH Guide for Grants and Contracts
Notice NOT-DA-23-044 from the NIH Guide for Grants and Contracts
Notice NOT-AI-23-073 from the NIH Guide for Grants and Contracts
Notice NOT-DC-24-007 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-25-052 from the NIH Guide for Grants and Contracts. There are gaps that prevent the utilization of decentralized clinical trials (DCT) in substance use area. The existing sensors for physiological measurement are rarely used and may need further validation. There are no wearable or home-use detection devices on the market capable to measure substances of interest (e.g., methadone, buprenorphine, their metabolites, as well as the spectrum of illicit drugs). The devices in development are not intended for diagnostics or treatment. Most of the devices are intended for laboratory use. Most of the devices do not have standard software interface through which the devices can transmit the data to the study center.
Funding Opportunity RFA-DA-25-051 from the NIH Guide for Grants and Contracts. There are gaps that prevent the utilization of decentralized clinical trials (DCT) in substance use area. The existing sensors for physiological measurement are rarely used and may need further validation. There are no wearable or home-use detection devices on the market capable to measure substances of interest (e.g., methadone, buprenorphine, their metabolites, as well as the spectrum of illicit drugs). The devices in development are not intended for diagnostics or treatment. Most of the devices are intended for laboratory use. Most of the devices do not have standard software interface through which the devices can transmit the data to the study center.
Notice NOT-GM-24-008 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-23-059 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support investigator-initiated research at all stages of development that is specifically focused on the development of medical countermeasures (MCMs) to mitigate/treat injuries arising from radiation exposure during a public health emergency. This funding opportunity will support the development of novel approaches within the radiation research area that may be considered for future licensure by the FDA.
Notice NOT-OD-24-015 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-25-002 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites cooperative agreement applications to expand the operational scope of the existing Human Pancreas Analysis Program (HPAP) to the study of pancreata recovered from tissue donors with Type 2 Diabetes (T2D) and related metabolic disorders. This NOFO will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; collection, processing and multimodal analysis of human pancreatic tissues; and biological database building, curation and management, that will be tasked to: 1) identify, collect and intensively characterize primary pancreatic tissues from patients with T2D and related forms of islet dysfunction, as well as age-matched controls; and 2) analyze, organize and share the data resulting from the study of these tissues through use and expansion of the existing PANC DB open-access resource database. HPAP is a component of the Human Islet Research Network (HIRN), created in 2014 to support innovative and collaborative translational research to understand how human beta cells are lost in Type 1 Diabetes (T1D), and to find innovative strategies to protect and replace functional human beta cell mass.
Notice NOT-CA-24-005 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-016 from the NIH Guide for Grants and Contracts
Notice NOT-DE-24-003 from the NIH Guide for Grants and Contracts
Notice NOT-CA-24-004 from the NIH Guide for Grants and Contracts
Notice NOT-AG-23-068 from the NIH Guide for Grants and Contracts
Notice to Close Funding Opportunity Announcement RFA-OH-22-001: NIOSH Education and Research Centers
Notice NOT-OH-24-001 from the NIH Guide for Grants and Contracts